Le infezioni in medicina · 2025
Back to normality? Respiratory viruses, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis trends: local epidemiological update after the COVID-19 storm.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avolio Manuela, Reffo Ingrid, Rigo Silvia, Fabro Giovanni Del, Costa Elena Garlatti, Marson Gloria, Grazioli Silvia, Nascimben Fabiana, Arcidiacono Domenico, De Santi Laura, Bianco Luca, Pellis Tommaso, Nadalin Gabriella, Crapis Massimo, Basaglia Giancarlo, Venturini Sergio
Аннотация
BACKGROUND: The COVID-19 pandemic deeply impacted the epidemiology of respiratory viruses and bacteria, including Mycoplasma pneumoniae (MP), Chlamydophila pneumoniae (CP), and Bordetella pertussis (BP). We have retrospectively examined the circulation patterns of major non-culturable respiratory pathogens that cause acute respiratory infections (ARIs) over four years (2021-2024), encompassing both the pandemic and post-pandemic phases.
METHODS: The study was conducted in the five hospitals of the Friuli Venezia Giulia region, in northeastern Italy from January 2021 to December 2024. A total of 11,208 respiratory samples from adult and pediatric patients displaying symptoms of ARIs, but negative for SARS-CoV-2, in accordance with our testing protocols, were tested for the following pathogens: influenza A and B (FLU A-B), adenovirus (ADV), coronaviruses (COV) 229E, NL63, OC43, bocavirus (BOV), enterovirus (EV), metapneumovirus (MPV), rhinovirus (RV), parainfluenza types 1-4 (PIV 1-4), respiratory syncytial virus A and B (RSV A/B), MP, CP, BP, and B. parapertussis (BPP).
RESULTS: The number of tests increased from 1,076 in 2021 to 4,377 in 2024. Overall positivity rates rose as follows: 27.4% (295/1,076) in 2021, 33.6% (714/2,125) in 2022, 41.3% (1,500/3,631) in 2023, and 47.2% (2,067/4,377) in 2024. RV, ADV, BOV, COV, PIV 1-4, MPV, and RSV A/B gradually returned to pre-pandemic circulation levels. FLU A-B, not detected in 2021, re-emerged in 2022. MP, BP, and CP, nearly absent in 2021 and 2022, reappeared in 2023.
CONCLUSION: This retrospective study assessed the circulation of respiratory viruses, MP, CP and BP in our geographical area, observing their gradual and asynchronous re-emergence following the COVID-19 pandemic. Strengthening advanced molecular microbiological diagnostics within clinical and epidemiological settings is crucial for supporting new surveillance models and promoting the judicious use of antibiotics.
METHODS: The study was conducted in the five hospitals of the Friuli Venezia Giulia region, in northeastern Italy from January 2021 to December 2024. A total of 11,208 respiratory samples from adult and pediatric patients displaying symptoms of ARIs, but negative for SARS-CoV-2, in accordance with our testing protocols, were tested for the following pathogens: influenza A and B (FLU A-B), adenovirus (ADV), coronaviruses (COV) 229E, NL63, OC43, bocavirus (BOV), enterovirus (EV), metapneumovirus (MPV), rhinovirus (RV), parainfluenza types 1-4 (PIV 1-4), respiratory syncytial virus A and B (RSV A/B), MP, CP, BP, and B. parapertussis (BPP).
RESULTS: The number of tests increased from 1,076 in 2021 to 4,377 in 2024. Overall positivity rates rose as follows: 27.4% (295/1,076) in 2021, 33.6% (714/2,125) in 2022, 41.3% (1,500/3,631) in 2023, and 47.2% (2,067/4,377) in 2024. RV, ADV, BOV, COV, PIV 1-4, MPV, and RSV A/B gradually returned to pre-pandemic circulation levels. FLU A-B, not detected in 2021, re-emerged in 2022. MP, BP, and CP, nearly absent in 2021 and 2022, reappeared in 2023.
CONCLUSION: This retrospective study assessed the circulation of respiratory viruses, MP, CP and BP in our geographical area, observing their gradual and asynchronous re-emergence following the COVID-19 pandemic. Strengthening advanced molecular microbiological diagnostics within clinical and epidemiological settings is crucial for supporting new surveillance models and promoting the judicious use of antibiotics.